Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
about
Rituximab use in adult primary glomerulopathy: where is the evidence?The efficacy of rituximab in adult frequently relapsing minimal change disease.The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome.Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndromeAdverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
P2860
Q28075564-DFEFB36F-8E7B-43A2-B974-B947B3D73FE3Q33793403-D9823B9D-E2FB-45F0-BC7E-4A9A13BFCE2AQ36098017-D01F8784-DFE7-4C3F-8535-181BED2388CAQ37261621-B908948E-2AC7-407C-A0EA-378482DE2218Q38679589-8A0F44DC-B1E3-4E44-827B-7B42E25F7660Q38896218-61238CCE-62D3-401B-BCB3-B301BD33B64BQ39335899-99536ECC-DD2C-41BB-82C4-E70D32BEF7AFQ39456170-D5B27854-3615-40EC-B22B-F0B9EA689846Q41124267-C7C10C10-7D96-4E11-BD91-63C29371C339Q42019934-83F028DB-B5B5-43E2-A4CA-4B02779801F5Q50047399-37F9DFA0-E132-412E-BAEF-A4A2AE7731C1
P2860
Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Rituximab for minimal-change n ...... g-term outcomes and tolerance.
@en
Rituximab for minimal-change n ...... g-term outcomes and tolerance.
@nl
type
label
Rituximab for minimal-change n ...... g-term outcomes and tolerance.
@en
Rituximab for minimal-change n ...... g-term outcomes and tolerance.
@nl
prefLabel
Rituximab for minimal-change n ...... g-term outcomes and tolerance.
@en
Rituximab for minimal-change n ...... g-term outcomes and tolerance.
@nl
P2093
P2860
P356
P1476
Rituximab for minimal-change n ...... g-term outcomes and tolerance.
@en
P2093
Anne-Laure Hebral
Benoit Vendrely
Claire Presne
Dominique Chauveau
Dominique Joly
Fadi Fakhouri
Françis Ducret
Jean-Claude Glachant
Joseph Rivalan
Joëlle Guitard
P2860
P304
P356
10.1093/NDT/GFU209
P407
P577
2014-06-11T00:00:00Z